Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
1(7%)
Results Posted
60%(6 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_4
7
50%
Ph not_applicable
2
14%
Ph phase_2
1
7%
Ph phase_3
3
21%

Phase Distribution

0

Early Stage

1

Mid Stage

10

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
3(23.1%)
Phase 4Post-market surveillance
7(53.8%)
N/ANon-phased studies
2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

1

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(10)
Terminated(3)

Detailed Status

Completed10
Terminated2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
1
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (7.7%)
Phase 33 (23.1%)
Phase 47 (53.8%)
N/A2 (15.4%)

Trials by Status

completed1071%
terminated214%
withdrawn17%
recruiting17%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT07400926

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Recruiting
NCT02390284Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

Terminated
NCT04615403Phase 2

Study of Exchange of Travoprost Intraocular Implant

Completed
NCT01444040Phase 4

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

Completed
NCT02914509Phase 3

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

Completed
NCT01443988Phase 4

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost

Completed
NCT01315574Phase 4

Effects of Anti-Glaucoma Medications on the Ocular Surface

Terminated
NCT02105311Phase 4

Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure

Completed
NCT01711177Not Applicable

Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma

Completed
NCT00705757Phase 4

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Completed
NCT01655758Phase 4

24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension

Completed
NCT00441181Not Applicable

Effects of Travoprost on Neovascular Glaucoma

Withdrawn
NCT00061503Phase 4

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

Completed
NCT00051142Phase 3

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Completed

All 14 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
14